[1]石曈 黄淑田.维利西呱及其抗心力衰竭的研究进展[J].心血管病学进展,2023,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.003]
　SHI Tong,HUANG Shutian.Vericiguat and Its Anti-Heart Failure[J].Advances in Cardiovascular Diseases,2023,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.003]
点击复制

维利西呱及其抗心力衰竭的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年5期
页码:
394
栏目:
综述
出版日期:
2023-05-25

文章信息/Info

Title:
Vericiguat and Its Anti-Heart Failure
作者:
石曈 黄淑田
(山西医科大学第二临床医学院,山西 太原 030001)
Author(s):
SHI Tong; HUANG Shutian
(The Second Hospital of Shanxi Medical University,Taiyuan 030001 ,Shanxi,China)
关键词:
心力衰竭; 可溶性鸟苷酸环化酶; 维利西呱
Keywords:
Heart failure; Soluble guanylate cyclase; Vericiguat
DOI:
10.16806/j.cnki.issn.1004-3934.2023.05.003
摘要:
心力衰竭（HF）是各种心脏疾病的临床终末阶段，是由多种原因引起心室充盈和/或射血功能受损，导致高住院率和发病率。根据2021年欧洲心脏病学会指南将其分为射血分数降低性HF（左室射血分数≤40%）、中间范围射血分数HF（左室射血分数为41%～49%）和射血分数保留性HF（左室射血分数≥50 %)。在过去的30年中，HF的药物治疗主要针对交感神经系统和肾素-血管紧张素-醛固酮系统，但大量数据表明，其疗法无法满足当前需求，HF治疗亟待更新。近年来，HF的新疗法发展迅速。伊伐布雷定、血管紧张素受体-脑啡肽酶抑制剂、钠-葡萄糖共转运蛋白2抑制剂、维利西呱等疗法已被证明能改善射血分数降低性HF患者的预后。维利西呱作为中国新上市的新型治疗HF的药物，是一种口服的可溶性鸟苷酸环化酶刺激剂。现就其作用机制、临床研究、安全性、与其他药物的联合使用做系统性综述，进一步为临床合理用药提供依据。
Abstract:
Heart failure(HF) is the clinical end stage of various heart diseases. It is due to a variety of causes of ventricular filling and/or impaired ejection function,resulting in high hospitalization and morbidity. According to the 2021 European Society of Cardiology guideline,it is divided into HF with reduced ejection fraction (left ventricular ejection fraction≤40%),HF with mid-range ejection fraction(left ventricular ejection fraction 41%～49%),and HF with preserved ejection fraction(left ventricular ejection fraction≥50%). In the past thirty years ,HF of drug treatment is aimed at the sympathetic nervous system and renin-angiotensin-aldosterone system,but a large amount of data showed that conventional therapies cannot meet the current needs, and HF treatment urgently needs to be updated. New therapy for HF has been rapidly developing in recent years. Therapies such as ivabradine,angiotensin receptor-neprilysin inhibitor,sodium-glucose cotransporter 2 inhibitor,and vericiguat have been proved to improve outcomes in patients with HF with reduced ejection fraction. Vericiguat as a new type of drug for the treatment of HF in China ,it is a new oral soluble guanylate cyclase stimulator. This article provides a systematic review of its mechanism of action,clinical research,safety,and combination with other drugs to provide further basis for clinical rational drug use

参考文献/References:

[1] Huang J,Yin H,Zhang M,et al. Understanding the economic burden of heart failure in China:impact on disease management and resource utilization[J]. J med econ,2017,20(5):549-553.

[2] Zhang Y,Zhang J,Butler J,et al. Contemporary epidemiology,management,and outcomes of patients hospitalized for heart failure in China:results from the China heart failure (China-HF) registry[J]. J Card Fail,2017,23(12):868-875.

[3] Markham A,Duggan S. Vericiguat:first approval[J]. Drugs,2021,81(6):721-726.

[4] Armstrong PW,Pieske B,Anstrom KJ,et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med,2020,382(20):1883-1893.

[5] Hulot JS,Trochu JN,Donal E,et al. Vericiguat for the treatment of heart failure:mechanism of action and pharmacological properties compared with other emerging therapeutic options[J]. Expert Opin Pharmacother,2021,22(14):1847-1855.

[6] Sandner P. From molecules to patients:exploring the therapeutic role of soluble guanylate cyclase stimulators[J]. Biol Chem,2018,399(7):679-690.

[7] Kong Q,Blanton RM. Protein kinase G I and heart failure:shifting focus from vascular unloading to direct myocardial antiremodeling effects[J]. Circ Heart Fail,2013,6(6):1268-1283.

[8] Gupta D,Georgiopoulou VV,Kalogeropoulos AP,et al. Nitrate therapy for heart failure:benefits and strategies to overcome tolerance[J]. JACC Heart Fail,2013,1(3):183-191.

[9] Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors[J]. Physiol Rev,2016,96(2):751-804.

[10] Ruehs H,Klein D,Frei M,et al. Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction[J]. Clin Pharmacokinet,2021,60(11):1407-1421.

[11] Nakai T,Perl NR,Barden TC,et al. Discovery of IWP-051,a novel orally bioavailable sGC stimulator with once-daily dosing potential in humans[J]. ACS Med Chem Lett,2016,7(5):465-469.

[12] Follmann M,Ackerstaff J,Redlich G,et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure[J]. J Med Chem,2017,60(12):5146-5161.

[13] Kramer F,Voss S,Roessig L,et al. Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction[J]. Eur J Heart Fail,2020,22(9):1675-1683.

[14] Breitenstein S,Roessig L,Sandner P,et al. Novel sGC stimulators and sGC activators for the treatment of heart failure[J]. Handb Exp Pharmacol,2017,243:225-247.

[15] Boettcher M,Thomas D,Mueck W,et al. Safety,pharmacodynamic,and pharmacokinetic characterization of vericiguat:results from six phase I studies in healthy subjects[J]. Eur J Clin Pharmacol,2021,77(4):527-537.

[16] Boettcher M,Gerisch M,Lobmeyer M,et al. Metabolism and Pharmacokinetic drug-drug interaction profile of vericiguat,a soluble guanylate cyclase stimulator:results from preclinical and phase I healthy volunteer studies[J]. Clin pharmacokinet,2020, 59(11):1407-1418.

[17] Xia J,Hui N,Tian L,et al. Development of vericiguat:the first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)[J]. Biomed Pharmacother,2022,149:112894.

[18] Abdin A,B?hm M. Renal function and vericiguat in heart failure patients:light at the end of the tunnel![J]. Eur J Heart Fail,2021,23(8):1322-1324.

[19] Voors AA,Mulder H,Reyes E,et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction:insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial[J]. Eur J Heart Fail,2021,23(8):1313-1321.

[20] D?bska-Koz?owska A,Ksi??czyk M,Lelonek M. Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations from new promising clinical trials[J]. Heart Fail Rev,2022,27(2):419-430.

[21] Peri-Okonny PA,Mi X,Khariton Y,et al. Target doses of heart failure medical therapy and blood pressure:insights from the CHAMP-HF registry[J]. JACC Heart Fail,2019,7(4):350-358.

[22] Lam CSP,Mulder H,Lopatin Y,et al. Blood pressure and safety events with vericiguat in the victoria trial[J]. J Am Heart Assoc,2021,10(22):e021094.

[23] Chaudhary AG,Alreefi FM,Aziz MA. Emerging pharmacologic therapies for heart failure with reduced ejection fraction[J]. CJC Open,2021,3(5):646-657.

[24] Gan H,Tang H,Huang Y,et al. The ‘diamond’ approach to personalized drug treatment of heart failure with reduced ejection fraction [J]. Rev Cardiovasc Med, 2021, 22(3):573-584.

[25] Yancy CW,Jessup M,Bozkurt B,et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of america[J]. Circulation,2017,136(6):e137-e161.

[26] McDonald M,Virani S,Chan M,et al. CCS/CHFS heart failure guidelines update:defining a new pharmacologic standard of care for heart failure with reduced ejection fraction[J]. Can J Cardiol,2021,37(4):531-546.

[27] Aimo A,Castiglione V,Vergaro G,et al. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction[J]. Heart Fail Rev,2022,27(4):1165-1171.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(5):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(5):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(5):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]高源 郑刚 李嫣红 张鼎.维利西呱治疗心力衰竭新进展[J].心血管病学进展,2021,(8):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]
　Gao Yuan Zheng Gang Li Yan Hong Zhang Ding.Treatment of Heart Failure with Vericiguat[J].Advances in Cardiovascular Diseases,2021,(5):698.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.007]

更新日期/Last Update: 2023-06-29